Actavis to buy Forest Labs in $25B deal

Tue, 02/18/2014 - 8:07am
The Associated Press

Actavis PLC says it will acquire fellow drugmaker Forest Laboratories Inc. in a cash-and-stock deal worth about $25 billion.

The deal would create a combined company spanning both generic and branded drugs, including Forest's Alzheimer's treatment Namenda and the antidepressant Lexapro.

Actavis will pay Forest shareholders $26.04 in cash and a portion of an Actavis share for each Forest share. The total, per-share price of $89.48 represents a premium of about 25 percent over Friday's closing price.

Dublin-based Actavis has grown rapidly through acquisition, including an $8.5 billion deal last year to buy another Irish drugmaker, Warner Chilcott.

New York-based Forest Labs has been squeezed by generic competition to some of its biggest drugs, including Lexapro. It has been working to cut costs under new CEO Brenton L. Saunders.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.